HHS Eyed Optimal Use Of Protease Inhibitors Even Before Victrelis Approval
Executive Summary
Even before FDA’s May 13 approval of Merck’s protease inhibitor Victrelis (boceprevir) for hepatitis C, federal health officials were eyeing the best way to maximize treatment with this new class of drugs.